FibroGen to effect 1-for-25 reverse stock split to regain Nasdaq compliance

KYNTRA BIO, INC.

Reverse split effective 5:00 p.m. ET June 16, 2025; post-split trading begins June 17.
Outstanding shares reduced from ~101.1M to ~4.0M; new CUSIP 31572Q881.
No fractional shares issued; cash paid in lieu of fractional interests.
Split approved by stockholders at June 4, 2025 annual meeting.
Aims to meet Nasdaq minimum bid price requirement (Rule 5450(a)(1)).

item 3.03item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.